JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

AnaptysBio Inc

Fechado

SetorSaúde

34.96 3.31

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.6

Máximo

35.04

Indicadores-chave

By Trading Economics

Rendimento

699K

-39M

Vendas

-5.5M

22M

Margem de lucro

-173.517

Funcionários

136

EBITDA

9.2M

-18M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+75.02% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

275M

987M

Abertura anterior

31.65

Fecho anterior

34.96

Sentimento de Notícias

By Acuity

50%

50%

147 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

AnaptysBio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de out. de 2025, 18:41 UTC

Ganhos

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 de out. de 2025, 18:31 UTC

Ganhos

Correction to Procter & Gamble to Focus on Innovation

24 de out. de 2025, 16:25 UTC

Grandes Movimentos do Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 de out. de 2025, 21:07 UTC

Ganhos

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 de out. de 2025, 20:58 UTC

Ganhos

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 de out. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 20:40 UTC

Ganhos

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 de out. de 2025, 20:24 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:23 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:13 UTC

Ganhos

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 20:07 UTC

Conversa de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 de out. de 2025, 19:40 UTC

Conversa de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 de out. de 2025, 19:35 UTC

Conversa de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 de out. de 2025, 19:33 UTC

Ganhos

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 de out. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 de out. de 2025, 18:52 UTC

Ganhos

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:41 UTC

Ganhos

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:03 UTC

Ganhos

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 de out. de 2025, 18:02 UTC

Ganhos

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 de out. de 2025, 18:00 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 de out. de 2025, 16:57 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 de out. de 2025, 16:54 UTC

Conversa de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 de out. de 2025, 16:44 UTC

Conversa de Mercado
Ganhos

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 de out. de 2025, 16:39 UTC

Conversa de Mercado
Ganhos

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 de out. de 2025, 16:33 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:23 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 16:07 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparação entre Pares

Variação de preço

AnaptysBio Inc Previsão

Preço-alvo

By TipRanks

75.02% parte superior

Previsão para 12 meses

Média 61.38 USD  75.02%

Máximo 90 USD

Mínimo 20 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para AnaptysBio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

9

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

19.25 / 21.135Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

147 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
help-icon Live chat